Replies to post #146466 on Biotech Values

[mcbio]

ARRY - I suppose another reason could be that since 614 is a p38 inhibitor as well there could be similar Qtc observations seen. Obviously that would not be a serious concern given that MDS is more severe.

That's an interesting point and I hadn't thought of that. But certainly agree there is a much greater threshold for safety issues in an MDS trial than pain trial. And I'm not so sure the safety issues are a showstopper even in the pain trial, provided they remain within the existing level at the dose planned going forward. That's not to say ARRY will be able to find a partner for pain as I do tend to agree with others that there will probably need to be large studies of sufficient duration to be conducted to rule out safety concerns in chronic pain setting.